Hugo ten Cate

Professor

Prof. Hugo ten Cate graduated in Medicine at the University of Amsterdam in 1987. The title of his PhD thesis was 'Clinical and experimental studies with a low molecular weight heparinoid'. Hugo had his post-doctoral training at the laboratory of Prof. Robert Rosenberg and Dr Kenneth Bauer at the Beth Israel Hospital and Harvard Medical School Boston on mechanisms of inflammation associated coagulation activity (1988-1990). He completed his internal medicine training in 1996 and became a general internist in conjunction with research at Academic Medical Center (laboratory of Experimental Internal medicine, Prof. Pieter Reitsma). He received a Clinical Established Investigator grant from the Dutch Heart Foundation in 1998.

In 2002, Hugo ten Cate was appointed Professor of Clinical Thrombosis and Haemostasis at CARIM. In addition, Prof. ten Cate was appointed adjunct professor at the Center for Thrombosis and Haemostasis (CTH) at Gutenberg University Medical Center, Mainz, Germany in 2017

Since the transfer to CARIM in 2002 his research focus shifted from coagulation-inflammation research in sepsis models, to the broader field of cardiovascular (CV) disease (atherothrombosis and 'thrombo-inflammation'). A specific focus of current research is the pleiotropic actions of coagulation proteases in atherosclerosis, atherothrombosis and ischemia reperfusion injury. Clinical research is aimed at chronic thrombotic disease including peripheral artery disease, high risk patients with coronary disease on antithrombotic medication and, together with Dr Arina ten Cate-Hoek, on venous thrombosis and post thrombotic syndrome (PTS). He is workpackage leader in CVON consortia RACE-5 (coagulation and its impact on atrial fibrillation) and CONTRAST (acute ischemic stroke) and involved in the ITN consortia TAPAS and TICARDIO. His group has an ongoing target finding programme with Bayer (steered from CARIM by Dr Henri Spronk and Prof. Hugo ten Cate) as well as with 2M (on POC development).

Department of Biochemistry
Department of Internal Medicine
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room number: 4.344
T: +31(0)43 388 42 62

  • 2021
    • de Breet, C. P. D. M., Zwaveling, S., Vries, M. J. A., van Oerle, R. G., Henskens, Y. M. C., Van't Hof, A. W. J., van der Meijden, P. E. J., Veenstra, L., ten Cate, H., & Olie, R. H. (2021). Thrombin Generation as a Method to Identify the Risk of Bleeding in High Clinical-Risk Patients Using Dual Antiplatelet Therapy. Frontiers in cardiovascular medicine, 8, [679934]. https://doi.org/10.3389/fcvm.2021.679934
    • Notten, P., de Smet, A. A. E. A., Tick, L. W., van de Poel, M. H. W., Wikkeling, O. R. M., Vleming, L-J., Koster, A., Jie, K-S. G., Jacobs, E. M. G., Ebben, H. P., Coppens, M., ten Cate, H., Wittens, C. H. A., & ten Cate-Hoek, A. J. (2021). CAVA (Ultrasound-Accelerated Catheter-Directed Thrombolysis on Preventing Post-Thrombotic Syndrome) Trial: Long-Term Follow-Up Results. Journal of the American Heart Association, 10(11), [018973]. https://doi.org/10.1161/JAHA.120.018973
    • Iding, A. F. J., Witten, A., Isaacs, A., Castoldi, E., ten Cate, H., Stoll, M., & ten Cate-Hoek, A. J. (2021). Leukocyte gene expression in post-thrombotic syndrome. Thrombosis Research, 202, 40-42. https://doi.org/10.1016/j.thromres.2021.03.007
    • Ninivaggi, M., de Laat-Kremers, R., Tripodi, A., Wahl, D., Zuily, S., Dargaud, Y., Cate, H. T., Ignjatovic, V., Devreese, K. M. J., & de Laat, B. (2021). Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Journal of Thrombosis and Haemostasis, 19(5), 1372-1378. https://doi.org/10.1111/jth.15287
    • ten Cate, H., & Leader, A. (2021). Management of Disseminated Intravascular Coagulation in Acute Leukemias. Hämostaseologie, 41(02), 120-126. https://doi.org/10.1055/a-1393-8302
  • 2020
    • Seelig, J., Hemels, M. E. W., Xhaet, O., Bongaerts, M. C. M., de Wolf, A., Groenemeijer, B. E., Heyse, A., Hoogslag, P., Voet, J., Herrman, J-P. R., Vervoort, G., Hermans, W., Wollaert, B., Boersma, L. V. A., Hermans, K., Lucassen, A., Verstraete, S., Adriaansen, H. J., Mairesse, G. H., ... GARFIELD-AF Investigators (2020). Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD-AF registry. Journal of Thrombosis and Haemostasis, 18(12), 3280-3288. https://doi.org/10.1111/jth.15081
    • Bavalia, R., Abdoellakhan, R., Beenen, L. F., Brekelmans, M. P. A., Olie, R. H., ten Cate, H., Huisman, M., Kruip, M., Middeldorp, S., Meijer, K., Hutten, B. A., & Coppens, M. (2020). Outcome of intracranial bleeding managed with prothrombin complex concentrate in patients on direct factor Xa inhibitors or vitamin K antagonists. Thrombosis Research, 196, 404-409. https://doi.org/10.1016/j.thromres.2020.09.028
    • Bruggemann, R. A. G., Spaetgens, B., Gietema, H. A., Brouns, S. H. A., Stassen, P. M., Magdelijns, F. J., Rennenberg, R. J., Henry, R. M. A., Mulder, M. M. G., van Bussel, B. C. T., Schnabel, R. M., van der Horst, I. C. C., Wildberger, J. E., Stehouwer, C. D. A., & ten Cate, H. (2020). The prevalence of pulmonary embolism in patients with COVID-19 and respiratory decline: A three-setting comparison. Thrombosis Research, 196, 486-490. https://doi.org/10.1016/j.thromres.2020.10.012
    • Busch, M. H., Timmermans, S. A. M. E. G., Nagy, M., Visser, M., Huckriede, J., Aendekerk, J. P., de Vries, F., Potjewijd, J., Jallah, B., Ysermans, R., Oude Lashof, A. M. L., Breedveld, P. H., van de Poll, M. C. G., van de Horst, I. C. C., van Bussel, B. C. T., Theunissen, R. O. M. F. I. H., Spronk, H. M. H., Damoiseaux, J. G. M. C., ten Cate, H., ... van Paassen, P. (2020). Neutrophils and Contact Activation of Coagulation as Potential Drivers of COVID-19. Circulation, 142(18), 1787-1790. https://doi.org/10.1161/CIRCULATIONAHA.120.050656
    • Chayoua, W., Yin, D., Kelchtermans, H., Moore, G. W., Gris, J-C., Musial, J., Zuily, S., ten Cate, H., de Laat, B., & Devreese, K. M. J. (2020). Is There an Additional Value in Detecting Anticardiolipin and Anti-β2 glycoprotein I IgA Antibodies in the Antiphospholipid Syndrome?Thrombosis and Haemostasis, 120(11), 1557-1568. https://doi.org/10.1055/s-0040-1714653